Table 2 Sensitivity and Specificity of PIVKA-II and AFP in differentiating HCC cases from controls at two fixed cut-off values.
Months before HCC diagnosis | Sensitivity | Specificity | Youden Index | Sensitivity | Specificity | Youden Index |
|---|---|---|---|---|---|---|
PIVKA-II (mAU/ml) | ≥32.0 | ≥100 | ||||
−12 | 31.4% | 93.5% | 24.9% | 2.9% | 100% | 2.9% |
−9 | 27.8% | 94.4% | 22.2% | 5.6% | 99.1% | 4.7% |
−6 | 38.9% | 92.6% | 31.5% | 8.3% | 100% | 8.3% |
−3 | 41.7% | 92.6% | 34.3% | 19.4% | 100% | 19.4% |
0 | 58.3% | 92.6% | 50.9% | 36.1% | 100% | 36.1% |
AFP (ng/ml) | ≥5.0 | ≥200 | ||||
−12 | 51.4% | 77.8% | 29.2% | 2.9% | 100% | 2.9% |
−9 | 47.2% | 77.8% | 25.0% | 0 | 100% | 0 |
−6 | 55.6% | 88.0% | 43.6% | 5.6% | 100% | 5.6% |
−3 | 66.7% | 88.9% | 55.6% | 16.7% | 100% | 16.7% |
0 | 75.0% | 91.7% | 66.7% | 19.4% | 100% | 19.4% |
AFP +PIVKA-II | ≥5.0 or * ≥32.0 | ≥5.0 and ** ≥32.0 | ||||
−12 | 27.8% | 75.9% | 3.7% | 13.8% | 98.1% | 11.9% |
−9 | 61.1% | 75.0% | 36.1% | 13.8% | 98.1% | 11.9% |
−6 | 72.2% | 82.4% | 54.6% | 22.2% | 99.1% | 21.3% |
−3 | 77.8% | 82.4% | 60.2% | 16.7% | 100% | 16.7% |
0 | 88.9% | 85.2% | 74.1% | 25.0% | 100% | 25.0% |
